Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Strub

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Molecular Cancer|January 28, 2021
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicityYann Cheli, Meri K Tulic, Najla El Hachem, et al.
Nature Communications|August 26, 2018
SIRT6 haploinsufficiency induces BRAF<sup>V600E</sup> melanoma cell resistance to MAPK inhibitors via IGF signallingThomas Strub, Flavia G Ghiraldini, Saul Carcamo, et al.
Molecular Cell|June 9, 2015
Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant MelanomaChiara Vardabasso, Alexandre Gaspar-Maia, Dan Hasson, et al.
Cell Death and Differentiation|January 19, 2021
Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic diseaseCharlotte Pandiani, Thomas Strub, Nicolas Nottet, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
Cell Death & Disease|October 24, 2025
SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic targetImène Krossa, Céline Pisibon, Yann Cheli, et al.
Journal of the National Cancer Institute|April 5, 2017
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma ProgressionCaroline Bonet, Flavie Luciani, Jean-François Ottavi, et al.
EMBO Molecular Medicine|November 15, 2023
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibitionSarah Proteau, Imène Krossa, Chrystel Husser, et al.
EMBO Molecular Medicine|August 20, 2024
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibitionSarah Proteau, Imène Krossa, Chrystel Husser, et al.
Nature|December 4, 2015
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinomaCorine Bertolotto, Fabienne Lesueur, Sandy Giuliano, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Molecular Cancer|January 28, 2021
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicityYann Cheli, Meri K Tulic, Najla El Hachem, et al.
Nature Communications|August 26, 2018
SIRT6 haploinsufficiency induces BRAF<sup>V600E</sup> melanoma cell resistance to MAPK inhibitors via IGF signallingThomas Strub, Flavia G Ghiraldini, Saul Carcamo, et al.
Molecular Cell|June 9, 2015
Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant MelanomaChiara Vardabasso, Alexandre Gaspar-Maia, Dan Hasson, et al.
Cell Death and Differentiation|January 19, 2021
Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic diseaseCharlotte Pandiani, Thomas Strub, Nicolas Nottet, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
Cell Death & Disease|October 24, 2025
SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic targetImène Krossa, Céline Pisibon, Yann Cheli, et al.
Journal of the National Cancer Institute|April 5, 2017
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma ProgressionCaroline Bonet, Flavie Luciani, Jean-François Ottavi, et al.
EMBO Molecular Medicine|November 15, 2023
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibitionSarah Proteau, Imène Krossa, Chrystel Husser, et al.
EMBO Molecular Medicine|August 20, 2024
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibitionSarah Proteau, Imène Krossa, Chrystel Husser, et al.
Nature|December 4, 2015
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinomaCorine Bertolotto, Fabienne Lesueur, Sandy Giuliano, et al.
Pageof 3